ArticleNeurobiology of disease2023

Terminal type-specific cannabinoid CB1 receptor alterations in patients with schizophrenia: A pilot study.

Shinnyi Chou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.